{"protocolSection": {"identificationModule": {"nctId": "NCT01484197", "orgStudyIdInfo": {"id": "CIDD001A2201"}, "secondaryIdInfos": [{"id": "2011-001825-25", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device", "officialTitle": "A Multi-centre, Randomized, Double-blind, Double-dummy, Multiple-dose, Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Orally Inhaled Indacaterol Administered as Either PulmoSphere or Lactose-blend Powder Via the Concept1 Device in Adult Patients With Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-11"}, "primaryCompletionDateStruct": {"date": "2012-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-11-15", "studyFirstSubmitQcDate": "2011-12-01", "studyFirstPostDateStruct": {"date": "2011-12-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-05-17", "resultsFirstSubmitQcDate": "2013-10-10", "resultsFirstPostDateStruct": {"date": "2013-12-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-03-18", "lastUpdatePostDateStruct": {"date": "2015-04-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will assess the pharmacodynamics, safety, tolerability and pharmacokinetics of two different formulations of indacaterol maleate, both administered via the Concept1 device. The study aims to determine whether the novel formulation has a similar clinical profile as the established formulation."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Indacaterol", "QAB149"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 36, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "75 \u00b5g Indacaterol (LB) + Placebo (PoS)", "type": "EXPERIMENTAL", "description": "75 \u00b5g indacaterol maleate lactose blend (LB) + placebo to indacterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.", "interventionNames": ["Drug: 75 \u00b5g indacaterol maleate (LB)", "Drug: placebo to indacaterol (PoS)"]}, {"label": "75 \u00b5g Indacaterol (PoS) + Placebo (LB)", "type": "EXPERIMENTAL", "description": "75 \u00b5g indacaterol maleate PulmoSphereTM (PoS) + placebo to indacterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.", "interventionNames": ["Drug: 75 \u00b5g indacaterol maleate (PoS)", "Drug: placebo to indacaterol (LB)"]}, {"label": "37.5 \u00b5g Indacaterol (PoS) + Placebo (LB)", "type": "EXPERIMENTAL", "description": "37.5 \u00b5g indacaterol maleate PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.", "interventionNames": ["Drug: 37.5 \u00b5g indacaterol maleate (PoS)", "Drug: placebo to indacaterol (LB)"]}, {"label": "Placebo (LB) and Placebo (PoS)", "type": "EXPERIMENTAL", "description": "Placebo to indacaterol PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.", "interventionNames": ["Drug: placebo to indacaterol (LB)", "Drug: placebo to indacaterol (PoS)"]}], "interventions": [{"type": "DRUG", "name": "75 \u00b5g indacaterol maleate (LB)", "description": "75 \u00b5g indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.", "armGroupLabels": ["75 \u00b5g Indacaterol (LB) + Placebo (PoS)"]}, {"type": "DRUG", "name": "75 \u00b5g indacaterol maleate (PoS)", "description": "75 \u00b5g indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.", "armGroupLabels": ["75 \u00b5g Indacaterol (PoS) + Placebo (LB)"]}, {"type": "DRUG", "name": "37.5 \u00b5g indacaterol maleate (PoS)", "description": "37.5 \u00b5g indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.", "armGroupLabels": ["37.5 \u00b5g Indacaterol (PoS) + Placebo (LB)"]}, {"type": "DRUG", "name": "placebo to indacaterol (LB)", "description": "Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.", "armGroupLabels": ["37.5 \u00b5g Indacaterol (PoS) + Placebo (LB)", "75 \u00b5g Indacaterol (PoS) + Placebo (LB)", "Placebo (LB) and Placebo (PoS)"]}, {"type": "DRUG", "name": "placebo to indacaterol (PoS)", "description": "Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.", "armGroupLabels": ["75 \u00b5g Indacaterol (LB) + Placebo (PoS)", "Placebo (LB) and Placebo (PoS)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Trough Forced Expiratory Volume in One Second (FEV1) After 7 Days of Treatment", "description": "Spirometry was performed according to internationally accepted standards at Day 8. Trough FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Trough FEV1 was defined as the average of the FEV1 measurements at 23 hours 10 minutes and 23 hours 45 minutes post dose.at Day 8. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.", "timeFrame": "Day 8"}], "secondaryOutcomes": [{"measure": "Trough Forced Expiratory Volume in One Second (FEV1) After 1 Day of Treatment", "description": "Spirometry was performed according to internationally accepted standards at Day 2. Trough FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Trough FEV1 was defined as the average of the FEV1 measurements at 23 hours 10 minutes and 23 hours 45 minutes post dose at Day 2. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.", "timeFrame": "Day 2"}, {"measure": "Peak FEV1 at Day 1 and Day 7", "description": "Spirometry was performed according to internationally accepted standards at 0, 15 and 30 minutes; 1,2,3,4,8,12 hours on Day 1 and 23.16 and 23.75 hours on Day 2 after 1 day of treatment and on Day 7 and Day 8 following 7 days of treatment. Peak FEV1 was the maximum FEV1 post treatment. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline included as a covariate.", "timeFrame": "Day 1, Day 7"}, {"measure": "Time to Peak FEV1 at Day 1 and Day 7", "description": "Spirometry was performed according to internationally accepted standards. Time to the peak (maximum) FEV1 is recorded. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.", "timeFrame": "Day 1, Day 7"}, {"measure": "FEV1 at Each Time-Point on Day 1 and Day 2", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8, 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.", "timeFrame": "Day 1, Day 2"}, {"measure": "FEV1 at Each Time-Point on Day 7 and Day 8", "description": "Spirometry was conducted according to internationally accepted standards at 0, 15 and 30 minutes; 1,2,3,4,8,12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.", "timeFrame": "Day 7, Day 8"}, {"measure": "Forced Vital Capacity (FVC) at Each Time-Point on Day 1 and Day 2", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FVC is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.", "timeFrame": "Day 1, Day 2"}, {"measure": "Forced Vital Capacity (FVC) at Each Time-Point on Day 7 and Day 8", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. FVC is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.", "timeFrame": "Day 7, Day 8"}, {"measure": "FEV1/FVC at Each Post-Dose Time Point on Day 1 and Day 2", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FEV1/FVC ratio is the percentage of the total FVC that is expelled from the lungs during the first second of forced exhalation.", "timeFrame": "Day1, Day 2"}, {"measure": "FEV1/FVC at Each Post-dose Time Point on Day 7 and Day 8", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2 after treatment. FEV1/FVC ratio is the percentage of the total FVC that is expelled from the lungs during the first second of forced exhalation.", "timeFrame": "Day 7, Day 8"}, {"measure": "Forced Expiratory Flow 25- 75% (FEF25-75) on Day 1 and Day 2", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. The forced expiratory flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.", "timeFrame": "Day 1, Day 2"}, {"measure": "Forced Expiratory Flow 25- 75% (FEF25-75) on Day 7 and Day 8", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. The forced expiratory flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.", "timeFrame": "Day 7, Day 8"}, {"measure": "Standardized FEV1 AUC Between Baseline (Pre-dose) and 4 Hour Post-dose (AUC0-4h)", "description": "Spirometry was conducted according to internationally accepted standards at predose, 5, 15 and 30 minutes, 1, 2 and 4 hours post-dose on Day 1 and Day 7. The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 4 h post. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.", "timeFrame": "Day 1, Day 7"}, {"measure": "Standardized FEV1 AUC Between Baseline (Pre-dose) and 12 Hour Post-dose (AUC0-12h)", "description": "Spirometry was conducted according to internationally accepted standards at predose, 5 , 15 and 30 min, 1, 2, 4, 8 and 12 hours post-dose on Day 1 and Day 7. The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 12 h post. Analysis of covariance with treatment, period, sequence and subject nested within sequence as fixed effects and FEV1 period baseline as a covariate.", "timeFrame": "Day 1, Day 7"}, {"measure": "Peak Expiratory Flow Rate in the Morning in the Evening", "description": "PEFR was measured on all days from Screening Visit 2 to end of study visit: twice daily pre-dose (prior to Inhaled Corticosteroids) and approximately 12 hours post-dose (during the treatment period). Each subject was provided with a PEFR meter and recorded the PEFR readings in a daily diary. repeated measures. Analysis of covariance with treatment, period, sequence, day and treatment-day interaction as fixed effect and subject as a random effect and baseline PEFR as a covariate in the model.", "timeFrame": "Up to 101 days"}, {"measure": "Number of Puffs of Rescue Medicine", "description": "Salbutamol (100 \u00b5g/puff) was used as rescued medicine. The total number of puffs per day was calculated and divided by the number of days with data to determine the mean daily number of puffs of rescue medication for each patient and was recorded in the patient diary from Baseline until Day 8 of Treatment Period 4. Analysis of covariance with treatment, period, sequence, and subject nested within sequence as fixed effect.", "timeFrame": "Up to 101 days"}, {"measure": "Number of Participants With Adverse Events as a Measure of Safety", "description": "Adverse event are defined as any unfavorable and unintended diagnosis, symptoms, sign (including an abnormal lab finding), syndrome or disease which either occurs during the study, having been absent at baseline, or if present at baseline appear to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization , cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards. Additional information about adverse events can be found in the Adverse Event section", "timeFrame": "Up to 101 days"}, {"measure": "Time to Reach Maximum Concentration (Tmax) After Drug Administration", "timeFrame": "Day1, Day 7"}, {"measure": "Observed Maximum Concentration (Cmax) After Drug Administration", "timeFrame": "Day 1, Day 7"}, {"measure": "Area Under the Curve Pre-dose to 24 Hour Post Dose (AUC0-24h)", "timeFrame": "Day 1, Day 7"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female patients with asthma\n* Aged 18 or above\n* Patients using inhaled corticosteroid (with or without long acting beta agonist)\n* Patients who demonstrate an increase in FEV1 after inhaling a short acting beta agonist\n\nExclusion Criteria:\n\n* Asthma exacerbations in previous 6 months\n* COPD or other pulmonary disease\n* Excessive use of short acting beta agonists", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Wiesbaden", "zip": "65187", "country": "Germany", "geoPoint": {"lat": 50.08258, "lon": 8.24932}}, {"facility": "Novartis Investigative Site", "city": "Machester", "zip": "M23 9QZ", "country": "United Kingdom"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Sequence 1", "description": "Treatment Period 1: 75 \u00b5g indacaterol maleate (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 2: placebo to indacterol (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 3: placebo to indacaterol (lactose blend) + 75 \u00b5g indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 4: placebo to indacaterol (lactose blend) + 37.5 \u00b5g Indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. All participants took part in a 7 day run-in period. There was a minimum 14 day washout between each treatment period. Participants continued their current treatment with Inhaled corticosteroids. Inhaled short-acting B2-agonist salbutamol was available for use as rescue medication throughout the study."}, {"id": "FG001", "title": "Sequence 2", "description": "Treatment Period 1: placebo to indacaterol (lactose blend) + 75 \u00b5g indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 2: 75 \u00b5g indacaterol maleate (lactose blend) + placebo to indacterol (PulmoSphereTM ) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 3: placebo to indacaterol (lactose blend) + 37.5 \u00b5g Indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 4: placebo to indacterol (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. All participants took part in a 7 day run-in period. There was a minimum 14 day washout between each treatment period. Participants continued their current treatment with Inhaled corticosteroids. Inhaled short-acting B2-agonist salbutamol was available for use as rescue medication throughout the study."}, {"id": "FG002", "title": "Sequence 3", "description": "Treatment Period 1: placebo to indacaterol (lactose blend) + 37.5 \u00b5g Indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 2: placebo to indacaterol (lactose blend) + 75 \u00b5g indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 3: placebo to indacterol (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 4: 75 \u00b5g indacaterol maleate (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. All participants took part in a 7 day run-in period. There was a minimum 14 day washout between each treatment period. Participants continued their current treatment with Inhaled corticosteroids. Inhaled short-acting B2-agonist salbutamol was available for use as rescue medication throughout the study."}, {"id": "FG003", "title": "Sequence 4", "description": "Treatment Period 1: placebo to indacterol (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 2: placebo to indacaterol (lactose blend) + 37.5 \u00b5g Indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 3: 75 \u00b5g indacaterol maleate (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 4: placebo to indacaterol (lactose blend) + 75 \u00b5g indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. All participants took part in a 7 day run-in period. There was a minimum 14 day washout between each treatment period. Participants continued their current treatment with Inhaled corticosteroids. Inhaled short-acting B2-agonist salbutamol was available for use as rescue medication throughout the study."}], "periods": [{"title": "Treatment Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Treatment Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "1 patient completed Period 1 but did not enter Period 2 due to a Protocol deviation.", "numSubjects": "7"}, {"groupId": "FG001", "comment": "1 patient completed Period 1 but did not enter Period 2 due to an Adverse event (AE).", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Subject withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}, {"title": "Treatment Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Treatment Period 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "comment": "2 patients completed Period 3 but did not enter Period 4 due to a Protocol deviation and an AE.", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Participants", "description": "All participants randomized to one of four treatment sequences."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "36"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45.8", "spread": "12.39"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "24"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Trough Forced Expiratory Volume in One Second (FEV1) After 7 Days of Treatment", "description": "Spirometry was performed according to internationally accepted standards at Day 8. Trough FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Trough FEV1 was defined as the average of the FEV1 measurements at 23 hours 10 minutes and 23 hours 45 minutes post dose.at Day 8. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Day 8", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "32"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.84", "spread": "0.03"}, {"groupId": "OG001", "value": "2.83", "spread": "0.03"}, {"groupId": "OG002", "value": "2.80", "spread": "0.03"}, {"groupId": "OG003", "value": "2.64", "spread": "0.03"}]}]}]}, {"type": "SECONDARY", "title": "Trough Forced Expiratory Volume in One Second (FEV1) After 1 Day of Treatment", "description": "Spirometry was performed according to internationally accepted standards at Day 2. Trough FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Trough FEV1 was defined as the average of the FEV1 measurements at 23 hours 10 minutes and 23 hours 45 minutes post dose at Day 2. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Day 2", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "33"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.83", "spread": "0.03"}, {"groupId": "OG001", "value": "2.84", "spread": "0.03"}, {"groupId": "OG002", "value": "2.81", "spread": "0.03"}, {"groupId": "OG003", "value": "2.62", "spread": "0.03"}]}]}]}, {"type": "SECONDARY", "title": "Peak FEV1 at Day 1 and Day 7", "description": "Spirometry was performed according to internationally accepted standards at 0, 15 and 30 minutes; 1,2,3,4,8,12 hours on Day 1 and 23.16 and 23.75 hours on Day 2 after 1 day of treatment and on Day 7 and Day 8 following 7 days of treatment. Peak FEV1 was the maximum FEV1 post treatment. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline included as a covariate.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Day 1, Day 7", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "33"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.08", "lowerLimit": "3.04", "upperLimit": "3.13"}, {"groupId": "OG001", "value": "3.11", "lowerLimit": "3.07", "upperLimit": "3.16"}, {"groupId": "OG002", "value": "3.05", "lowerLimit": "3.01", "upperLimit": "3.10"}, {"groupId": "OG003", "value": "2.85", "lowerLimit": "2.80", "upperLimit": "2.89"}]}]}, {"title": "Day 7 (n=33,30,32,33)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.09", "lowerLimit": "3.05", "upperLimit": "3.13"}, {"groupId": "OG001", "value": "3.11", "lowerLimit": "3.06", "upperLimit": "3.15"}, {"groupId": "OG002", "value": "3.10", "lowerLimit": "3.06", "upperLimit": "3.14"}, {"groupId": "OG003", "value": "2.89", "lowerLimit": "2.85", "upperLimit": "2.93"}]}]}]}, {"type": "SECONDARY", "title": "Time to Peak FEV1 at Day 1 and Day 7", "description": "Spirometry was performed according to internationally accepted standards. Time to the peak (maximum) FEV1 is recorded. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Hours", "timeFrame": "Day 1, Day 7", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "33"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.98", "lowerLimit": "0.25", "upperLimit": "23.77"}, {"groupId": "OG001", "value": "3.02", "lowerLimit": "0.25", "upperLimit": "23.75"}, {"groupId": "OG002", "value": "3.00", "lowerLimit": "0.25", "upperLimit": "23.75"}, {"groupId": "OG003", "value": "3.00", "lowerLimit": "0.25", "upperLimit": "24.77"}]}]}, {"title": "Day 7 (n=33,30,32,33)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.00", "lowerLimit": "0.22", "upperLimit": "23.82"}, {"groupId": "OG001", "value": "3.05", "lowerLimit": "0.25", "upperLimit": "23.77"}, {"groupId": "OG002", "value": "3.00", "lowerLimit": "0.98", "upperLimit": "23.78"}, {"groupId": "OG003", "value": "3.97", "lowerLimit": "0.25", "upperLimit": "23.77"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 at Each Time-Point on Day 1 and Day 2", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8, 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Day 1, Day 2", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "33"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"title": "0 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.61", "spread": "0.71"}, {"groupId": "OG001", "value": "2.65", "spread": "0.70"}, {"groupId": "OG002", "value": "2.68", "spread": "0.68"}, {"groupId": "OG003", "value": "2.67", "spread": "0.69"}]}]}, {"title": "5 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.85", "spread": "0.76"}, {"groupId": "OG001", "value": "2.97", "spread": "0.80"}, {"groupId": "OG002", "value": "2.90", "spread": "0.75"}, {"groupId": "OG003", "value": "2.66", "spread": "0.69"}]}]}, {"title": "30 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.86", "spread": "0.76"}, {"groupId": "OG001", "value": "2.96", "spread": "0.75"}, {"groupId": "OG002", "value": "2.93", "spread": "0.73"}, {"groupId": "OG003", "value": "2.70", "spread": "0.71"}]}]}, {"title": "1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.89", "spread": "0.76"}, {"groupId": "OG001", "value": "3.03", "spread": "0.80"}, {"groupId": "OG002", "value": "2.95", "spread": "0.75"}, {"groupId": "OG003", "value": "2.73", "spread": "0.72"}]}]}, {"title": "2 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.98", "spread": "0.73"}, {"groupId": "OG001", "value": "3.06", "spread": "0.81"}, {"groupId": "OG002", "value": "3.02", "spread": "0.74"}, {"groupId": "OG003", "value": "2.82", "spread": "0.68"}]}]}, {"title": "3 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.98", "spread": "0.76"}, {"groupId": "OG001", "value": "3.09", "spread": "0.80"}, {"groupId": "OG002", "value": "3.05", "spread": "0.75"}, {"groupId": "OG003", "value": "2.80", "spread": "0.69"}]}]}, {"title": "4 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.99", "spread": "0.73"}, {"groupId": "OG001", "value": "3.07", "spread": "0.81"}, {"groupId": "OG002", "value": "3.00", "spread": "0.75"}, {"groupId": "OG003", "value": "2.77", "spread": "0.67"}]}]}, {"title": "8 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.80", "spread": "0.60"}, {"groupId": "OG001", "value": "2.99", "spread": "0.83"}, {"groupId": "OG002", "value": "2.89", "spread": "0.79"}, {"groupId": "OG003", "value": "2.70", "spread": "0.68"}]}]}, {"title": "12 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.74", "spread": "0.65"}, {"groupId": "OG001", "value": "2.92", "spread": "0.79"}, {"groupId": "OG002", "value": "2.85", "spread": "0.79"}, {"groupId": "OG003", "value": "2.71", "spread": "0.67"}]}]}, {"title": "23.16 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.81", "spread": "0.74"}, {"groupId": "OG001", "value": "2.85", "spread": "0.77"}, {"groupId": "OG002", "value": "2.83", "spread": "0.76"}, {"groupId": "OG003", "value": "2.59", "spread": "0.69"}]}]}, {"title": "23.75 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.89", "spread": "0.75"}, {"groupId": "OG001", "value": "2.88", "spread": "0.80"}, {"groupId": "OG002", "value": "2.85", "spread": "0.72"}, {"groupId": "OG003", "value": "2.68", "spread": "0.69"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 at Each Time-Point on Day 7 and Day 8", "description": "Spirometry was conducted according to internationally accepted standards at 0, 15 and 30 minutes; 1,2,3,4,8,12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Day 7, Day 8", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "32"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"title": "0 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.80", "spread": "0.77"}, {"groupId": "OG001", "value": "2.79", "spread": "0.72"}, {"groupId": "OG002", "value": "2.85", "spread": "0.73"}, {"groupId": "OG003", "value": "2.63", "spread": "0.67"}]}]}, {"title": "15 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.87", "spread": "0.80"}, {"groupId": "OG001", "value": "2.88", "spread": "0.77"}, {"groupId": "OG002", "value": "2.92", "spread": "0.76"}, {"groupId": "OG003", "value": "2.65", "spread": "0.72"}]}]}, {"title": "30 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.91", "spread": "0.79"}, {"groupId": "OG001", "value": "2.92", "spread": "0.76"}, {"groupId": "OG002", "value": "2.94", "spread": "0.77"}, {"groupId": "OG003", "value": "2.64", "spread": "0.72"}]}]}, {"title": "1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.94", "spread": "0.75"}, {"groupId": "OG001", "value": "2.96", "spread": "0.77"}, {"groupId": "OG002", "value": "2.97", "spread": "0.76"}, {"groupId": "OG003", "value": "2.72", "spread": "0.70"}]}]}, {"title": "2 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.99", "spread": "0.76"}, {"groupId": "OG001", "value": "3.00", "spread": "0.72"}, {"groupId": "OG002", "value": "3.00", "spread": "0.73"}, {"groupId": "OG003", "value": "2.79", "spread": "0.72"}]}]}, {"title": "3 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.99", "spread": "0.74"}, {"groupId": "OG001", "value": "2.99", "spread": "0.75"}, {"groupId": "OG002", "value": "3.06", "spread": "0.75"}, {"groupId": "OG003", "value": "2.79", "spread": "0.72"}]}]}, {"title": "4 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.98", "spread": "0.75"}, {"groupId": "OG001", "value": "2.98", "spread": "0.73"}, {"groupId": "OG002", "value": "3.02", "spread": "0.70"}, {"groupId": "OG003", "value": "2.78", "spread": "0.70"}]}]}, {"title": "8 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.82", "spread": "0.64"}, {"groupId": "OG001", "value": "2.88", "spread": "0.77"}, {"groupId": "OG002", "value": "2.89", "spread": "0.75"}, {"groupId": "OG003", "value": "2.76", "spread": "0.65"}]}]}, {"title": "12 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.76", "spread": "0.66"}, {"groupId": "OG001", "value": "2.80", "spread": "0.78"}, {"groupId": "OG002", "value": "2.82", "spread": "0.76"}, {"groupId": "OG003", "value": "2.65", "spread": "0.70"}]}]}, {"title": "23.16 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.79", "spread": "0.71"}, {"groupId": "OG001", "value": "2.79", "spread": "0.77"}, {"groupId": "OG002", "value": "2.79", "spread": "0.79"}, {"groupId": "OG003", "value": "2.64", "spread": "0.68"}]}]}, {"title": "23.75 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.89", "spread": "0.72"}, {"groupId": "OG001", "value": "2.87", "spread": "0.76"}, {"groupId": "OG002", "value": "2.87", "spread": "0.74"}, {"groupId": "OG003", "value": "2.74", "spread": "0.68"}]}]}]}, {"type": "SECONDARY", "title": "Forced Vital Capacity (FVC) at Each Time-Point on Day 1 and Day 2", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FVC is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Day 1, Day 2", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "33"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"title": "0 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.11", "spread": "1.02"}, {"groupId": "OG001", "value": "4.30", "spread": "0.98"}, {"groupId": "OG002", "value": "4.23", "spread": "1.03"}, {"groupId": "OG003", "value": "4.27", "spread": "1.02"}]}]}, {"title": "15 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.29", "spread": "1.07"}, {"groupId": "OG001", "value": "4.52", "spread": "1.10"}, {"groupId": "OG002", "value": "4.34", "spread": "1.04"}, {"groupId": "OG003", "value": "4.25", "spread": "1.03"}]}]}, {"title": "30 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.29", "spread": "1.03"}, {"groupId": "OG001", "value": "4.47", "spread": "1.02"}, {"groupId": "OG002", "value": "4.39", "spread": "1.01"}, {"groupId": "OG003", "value": "4.18", "spread": "1.07"}]}]}, {"title": "1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.33", "spread": "1.06"}, {"groupId": "OG001", "value": "4.49", "spread": "1.05"}, {"groupId": "OG002", "value": "4.38", "spread": "1.06"}, {"groupId": "OG003", "value": "4.30", "spread": "1.06"}]}]}, {"title": "2 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.39", "spread": "0.99"}, {"groupId": "OG001", "value": "4.54", "spread": "1.07"}, {"groupId": "OG002", "value": "4.45", "spread": "1.02"}, {"groupId": "OG003", "value": "4.36", "spread": "0.97"}]}]}, {"title": "3 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.38", "spread": "1.04"}, {"groupId": "OG001", "value": "4.52", "spread": "1.05"}, {"groupId": "OG002", "value": "4.44", "spread": "0.98"}, {"groupId": "OG003", "value": "4.33", "spread": "0.98"}]}]}, {"title": "4 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.39", "spread": "1.01"}, {"groupId": "OG001", "value": "4.54", "spread": "1.06"}, {"groupId": "OG002", "value": "4.40", "spread": "1.01"}, {"groupId": "OG003", "value": "4.30", "spread": "0.98"}]}]}, {"title": "8 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.20", "spread": "0.86"}, {"groupId": "OG001", "value": "4.51", "spread": "1.09"}, {"groupId": "OG002", "value": "4.35", "spread": "1.07"}, {"groupId": "OG003", "value": "4.21", "spread": "1.01"}]}]}, {"title": "12 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.16", "spread": "0.93"}, {"groupId": "OG001", "value": "4.42", "spread": "1.05"}, {"groupId": "OG002", "value": "4.29", "spread": "1.04"}, {"groupId": "OG003", "value": "4.24", "spread": "1.02"}]}]}, {"title": "23.16 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.34", "spread": "1.06"}, {"groupId": "OG001", "value": "4.44", "spread": "1.08"}, {"groupId": "OG002", "value": "4.31", "spread": "1.08"}, {"groupId": "OG003", "value": "4.21", "spread": "0.99"}]}]}, {"title": "23.75 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.41", "spread": "1.06"}, {"groupId": "OG001", "value": "4.41", "spread": "1.10"}, {"groupId": "OG002", "value": "4.36", "spread": "1.08"}, {"groupId": "OG003", "value": "4.30", "spread": "0.99"}]}]}]}, {"type": "SECONDARY", "title": "Forced Vital Capacity (FVC) at Each Time-Point on Day 7 and Day 8", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. FVC is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Day 7, Day 8", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "32"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"title": "0 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.28", "spread": "1.07"}, {"groupId": "OG001", "value": "4.30", "spread": "0.93"}, {"groupId": "OG002", "value": "4.35", "spread": "1.06"}, {"groupId": "OG003", "value": "4.22", "spread": "1.00"}]}]}, {"title": "15 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.34", "spread": "1.09"}, {"groupId": "OG001", "value": "4.33", "spread": "0.95"}, {"groupId": "OG002", "value": "4.36", "spread": "1.06"}, {"groupId": "OG003", "value": "4.21", "spread": "1.04"}]}]}, {"title": "30 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.36", "spread": "1.08"}, {"groupId": "OG001", "value": "4.36", "spread": "0.96"}, {"groupId": "OG002", "value": "4.37", "spread": "1.06"}, {"groupId": "OG003", "value": "4.21", "spread": "1.04"}]}]}, {"title": "1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.37", "spread": "1.06"}, {"groupId": "OG001", "value": "4.35", "spread": "0.97"}, {"groupId": "OG002", "value": "4.41", "spread": "1.05"}, {"groupId": "OG003", "value": "4.28", "spread": "1.03"}]}]}, {"title": "2 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.39", "spread": "1.04"}, {"groupId": "OG001", "value": "4.40", "spread": "0.90"}, {"groupId": "OG002", "value": "4.42", "spread": "1.02"}, {"groupId": "OG003", "value": "4.37", "spread": "1.06"}]}]}, {"title": "3 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.37", "spread": "1.01"}, {"groupId": "OG001", "value": "4.40", "spread": "0.93"}, {"groupId": "OG002", "value": "4.46", "spread": "1.03"}, {"groupId": "OG003", "value": "4.34", "spread": "1.05"}]}]}, {"title": "4 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.38", "spread": "1.05"}, {"groupId": "OG001", "value": "4.39", "spread": "0.91"}, {"groupId": "OG002", "value": "4.44", "spread": "0.99"}, {"groupId": "OG003", "value": "4.32", "spread": "1.03"}]}]}, {"title": "8 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.24", "spread": "0.97"}, {"groupId": "OG001", "value": "4.29", "spread": "0.94"}, {"groupId": "OG002", "value": "4.31", "spread": "1.05"}, {"groupId": "OG003", "value": "4.31", "spread": "1.01"}]}]}, {"title": "12 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.17", "spread": "0.98"}, {"groupId": "OG001", "value": "4.23", "spread": "0.94"}, {"groupId": "OG002", "value": "4.25", "spread": "1.04"}, {"groupId": "OG003", "value": "4.21", "spread": "1.03"}]}]}, {"title": "23.16 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.32", "spread": "1.08"}, {"groupId": "OG001", "value": "4.30", "spread": "0.97"}, {"groupId": "OG002", "value": "4.29", "spread": "1.08"}, {"groupId": "OG003", "value": "4.28", "spread": "1.02"}]}]}, {"title": "23.75 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.41", "spread": "1.08"}, {"groupId": "OG001", "value": "4.34", "spread": "0.97"}, {"groupId": "OG002", "value": "4.34", "spread": "1.08"}, {"groupId": "OG003", "value": "4.36", "spread": "1.02"}]}]}]}, {"type": "SECONDARY", "title": "FEV1/FVC at Each Post-Dose Time Point on Day 1 and Day 2", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FEV1/FVC ratio is the percentage of the total FVC that is expelled from the lungs during the first second of forced exhalation.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Day1, Day 2", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "34"}, {"groupId": "OG002", "value": "34"}, {"groupId": "OG003", "value": "34"}]}], "classes": [{"title": "0 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.63", "spread": "0.08"}, {"groupId": "OG001", "value": "0.62", "spread": "0.08"}, {"groupId": "OG002", "value": "0.64", "spread": "0.09"}, {"groupId": "OG003", "value": "0.63", "spread": "0.09"}]}]}, {"title": "15 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.67", "spread": "0.08"}, {"groupId": "OG001", "value": "0.66", "spread": "0.07"}, {"groupId": "OG002", "value": "0.67", "spread": "0.09"}, {"groupId": "OG003", "value": "0.63", "spread": "0.09"}]}]}, {"title": "30 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.67", "spread": "0.07"}, {"groupId": "OG001", "value": "0.66", "spread": "0.07"}, {"groupId": "OG002", "value": "0.67", "spread": "0.08"}, {"groupId": "OG003", "value": "0.65", "spread": "0.09"}]}]}, {"title": "1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.67", "spread": "0.07"}, {"groupId": "OG001", "value": "0.67", "spread": "0.07"}, {"groupId": "OG002", "value": "0.68", "spread": "0.08"}, {"groupId": "OG003", "value": "0.64", "spread": "0.08"}]}]}, {"title": "2 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.68", "spread": "0.08"}, {"groupId": "OG001", "value": "0.67", "spread": "0.07"}, {"groupId": "OG002", "value": "0.68", "spread": "0.08"}, {"groupId": "OG003", "value": "0.65", "spread": "0.08"}]}]}, {"title": "3 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.68", "spread": "0.08"}, {"groupId": "OG001", "value": "0.68", "spread": "0.07"}, {"groupId": "OG002", "value": "0.69", "spread": "0.08"}, {"groupId": "OG003", "value": "0.65", "spread": "0.08"}]}]}, {"title": "4 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.68", "spread": "0.08"}, {"groupId": "OG001", "value": "0.67", "spread": "0.07"}, {"groupId": "OG002", "value": "0.68", "spread": "0.08"}, {"groupId": "OG003", "value": "0.65", "spread": "0.08"}]}]}, {"title": "8 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.67", "spread": "0.07"}, {"groupId": "OG001", "value": "0.66", "spread": "0.07"}, {"groupId": "OG002", "value": "0.67", "spread": "0.08"}, {"groupId": "OG003", "value": "0.64", "spread": "0.07"}]}]}, {"title": "12 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.66", "spread": "0.08"}, {"groupId": "OG001", "value": "0.66", "spread": "0.07"}, {"groupId": "OG002", "value": "0.66", "spread": "0.08"}, {"groupId": "OG003", "value": "0.64", "spread": "0.08"}]}]}, {"title": "23.16 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.65", "spread": "0.09"}, {"groupId": "OG001", "value": "0.64", "spread": "0.08"}, {"groupId": "OG002", "value": "0.66", "spread": "0.09"}, {"groupId": "OG003", "value": "0.62", "spread": "0.09"}]}]}, {"title": "23.75 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.66", "spread": "0.08"}, {"groupId": "OG001", "value": "0.65", "spread": "0.08"}, {"groupId": "OG002", "value": "0.66", "spread": "0.08"}, {"groupId": "OG003", "value": "0.63", "spread": "0.08"}]}]}]}, {"type": "SECONDARY", "title": "FEV1/FVC at Each Post-dose Time Point on Day 7 and Day 8", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2 after treatment. FEV1/FVC ratio is the percentage of the total FVC that is expelled from the lungs during the first second of forced exhalation.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Day 7, Day 8", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "32"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"title": "0 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.65", "spread": "0.08"}, {"groupId": "OG001", "value": "0.65", "spread": "0.07"}, {"groupId": "OG002", "value": "0.65", "spread": "0.08"}, {"groupId": "OG003", "value": "0.62", "spread": "0.08"}]}]}, {"title": "15 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.66", "spread": "0.08"}, {"groupId": "OG001", "value": "0.66", "spread": "0.07"}, {"groupId": "OG002", "value": "0.67", "spread": "0.07"}, {"groupId": "OG003", "value": "0.63", "spread": "0.08"}]}]}, {"title": "30 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.67", "spread": "0.08"}, {"groupId": "OG001", "value": "0.67", "spread": "0.06"}, {"groupId": "OG002", "value": "0.67", "spread": "0.07"}, {"groupId": "OG003", "value": "0.63", "spread": "0.09"}]}]}, {"title": "1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.67", "spread": "0.07"}, {"groupId": "OG001", "value": "0.68", "spread": "0.07"}, {"groupId": "OG002", "value": "0.67", "spread": "0.07"}, {"groupId": "OG003", "value": "0.64", "spread": "0.08"}]}]}, {"title": "2 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.68", "spread": "0.07"}, {"groupId": "OG001", "value": "0.68", "spread": "0.06"}, {"groupId": "OG002", "value": "0.68", "spread": "0.07"}, {"groupId": "OG003", "value": "0.64", "spread": "0.08"}]}]}, {"title": "3 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.68", "spread": "0.07"}, {"groupId": "OG001", "value": "0.68", "spread": "0.07"}, {"groupId": "OG002", "value": "0.69", "spread": "0.08"}, {"groupId": "OG003", "value": "0.65", "spread": "0.09"}]}]}, {"title": "4 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.68", "spread": "0.07"}, {"groupId": "OG001", "value": "0.68", "spread": "0.07"}, {"groupId": "OG002", "value": "0.68", "spread": "0.07"}, {"groupId": "OG003", "value": "0.64", "spread": "0.08"}]}]}, {"title": "8 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.66", "spread": "0.07"}, {"groupId": "OG001", "value": "0.67", "spread": "0.07"}, {"groupId": "OG002", "value": "0.67", "spread": "0.08"}, {"groupId": "OG003", "value": "0.64", "spread": "0.08"}]}]}, {"title": "12 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.66", "spread": "0.08"}, {"groupId": "OG001", "value": "0.66", "spread": "0.07"}, {"groupId": "OG002", "value": "0.66", "spread": "0.08"}, {"groupId": "OG003", "value": "0.63", "spread": "0.08"}]}]}, {"title": "23.16 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.64", "spread": "0.67"}, {"groupId": "OG001", "value": "0.65", "spread": "0.08"}, {"groupId": "OG002", "value": "0.65", "spread": "0.08"}, {"groupId": "OG003", "value": "0.62", "spread": "0.09"}]}]}, {"title": "23.75 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.65", "spread": "0.72"}, {"groupId": "OG001", "value": "0.66", "spread": "0.07"}, {"groupId": "OG002", "value": "0.66", "spread": "0.08"}, {"groupId": "OG003", "value": "0.63", "spread": "0.09"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Flow 25- 75% (FEF25-75) on Day 1 and Day 2", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. The forced expiratory flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters/second", "timeFrame": "Day 1, Day 2", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "33"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"title": "0 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.55", "spread": "0.68"}, {"groupId": "OG001", "value": "1.52", "spread": "0.70"}, {"groupId": "OG002", "value": "1.54", "spread": "0.67"}, {"groupId": "OG003", "value": "1.56", "spread": "0.71"}]}]}, {"title": "15 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.78", "spread": "0.75"}, {"groupId": "OG001", "value": "1.81", "spread": "0.79"}, {"groupId": "OG002", "value": "1.82", "spread": "0.77"}, {"groupId": "OG003", "value": "1.54", "spread": "0.72"}]}]}, {"title": "30 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.80", "spread": "0.80"}, {"groupId": "OG001", "value": "1.82", "spread": "0.77"}, {"groupId": "OG002", "value": "1.84", "spread": "0.73"}, {"groupId": "OG003", "value": "1.61", "spread": "0.74"}]}]}, {"title": "1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.79", "spread": "0.77"}, {"groupId": "OG001", "value": "1.95", "spread": "0.85"}, {"groupId": "OG002", "value": "1.89", "spread": "0.75"}, {"groupId": "OG003", "value": "1.59", "spread": "0.73"}]}]}, {"title": "2 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.90", "spread": "0.80"}, {"groupId": "OG001", "value": "1.93", "spread": "0.84"}, {"groupId": "OG002", "value": "1.92", "spread": "0.79"}, {"groupId": "OG003", "value": "1.68", "spread": "0.74"}]}]}, {"title": "3 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.89", "spread": "0.81"}, {"groupId": "OG001", "value": "2.01", "spread": "0.83"}, {"groupId": "OG002", "value": "1.99", "spread": "0.85"}, {"groupId": "OG003", "value": "1.68", "spread": "0.77"}]}]}, {"title": "4 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.94", "spread": "0.82"}, {"groupId": "OG001", "value": "1.94", "spread": "0.85"}, {"groupId": "OG002", "value": "1.92", "spread": "0.80"}, {"groupId": "OG003", "value": "1.65", "spread": "0.70"}]}]}, {"title": "8 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.71", "spread": "0.69"}, {"groupId": "OG001", "value": "1.83", "spread": "0.84"}, {"groupId": "OG002", "value": "1.79", "spread": "0.81"}, {"groupId": "OG003", "value": "1.59", "spread": "0.66"}]}]}, {"title": "12 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.63", "spread": "0.65"}, {"groupId": "OG001", "value": "1.77", "spread": "0.78"}, {"groupId": "OG002", "value": "1.76", "spread": "0.83"}, {"groupId": "OG003", "value": "1.61", "spread": "0.69"}]}]}, {"title": "23.16 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.70", "spread": "0.77"}, {"groupId": "OG001", "value": "1.68", "spread": "0.75"}, {"groupId": "OG002", "value": "1.78", "spread": "0.80"}, {"groupId": "OG003", "value": "1.51", "spread": "0.70"}]}]}, {"title": "23.75 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.77", "spread": "0.74"}, {"groupId": "OG001", "value": "1.76", "spread": "0.77"}, {"groupId": "OG002", "value": "1.75", "spread": "0.71"}, {"groupId": "OG003", "value": "1.56", "spread": "0.71"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Flow 25- 75% (FEF25-75) on Day 7 and Day 8", "description": "Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. The forced expiratory flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters/second", "timeFrame": "Day 7, Day 8", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "32"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"title": "0 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.70", "spread": "0.75"}, {"groupId": "OG001", "value": "1.69", "spread": "0.76"}, {"groupId": "OG002", "value": "1.71", "spread": "0.78"}, {"groupId": "OG003", "value": "1.51", "spread": "0.67"}]}]}, {"title": "15 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.76", "spread": "0.83"}, {"groupId": "OG001", "value": "1.78", "spread": "0.82"}, {"groupId": "OG002", "value": "1.83", "spread": "0.80"}, {"groupId": "OG003", "value": "1.54", "spread": "0.73"}]}]}, {"title": "30 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.80", "spread": "0.79"}, {"groupId": "OG001", "value": "1.80", "spread": "0.82"}, {"groupId": "OG002", "value": "1.83", "spread": "0.81"}, {"groupId": "OG003", "value": "1.57", "spread": "0.72"}]}]}, {"title": "1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.82", "spread": "0.77"}, {"groupId": "OG001", "value": "1.89", "spread": "0.84"}, {"groupId": "OG002", "value": "1.87", "spread": "0.80"}, {"groupId": "OG003", "value": "1.61", "spread": "0.69"}]}]}, {"title": "2 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.88", "spread": "0.80"}, {"groupId": "OG001", "value": "1.89", "spread": "0.77"}, {"groupId": "OG002", "value": "1.91", "spread": "0.82"}, {"groupId": "OG003", "value": "1.64", "spread": "0.72"}]}]}, {"title": "3 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.91", "spread": "0.80"}, {"groupId": "OG001", "value": "1.88", "spread": "0.81"}, {"groupId": "OG002", "value": "2.02", "spread": "0.82"}, {"groupId": "OG003", "value": "1.69", "spread": "0.70"}]}]}, {"title": "4 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.90", "spread": "0.82"}, {"groupId": "OG001", "value": "1.88", "spread": "0.82"}, {"groupId": "OG002", "value": "1.93", "spread": "0.83"}, {"groupId": "OG003", "value": "1.65", "spread": "0.73"}]}]}, {"title": "8 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.71", "spread": "0.66"}, {"groupId": "OG001", "value": "1.80", "spread": "0.82"}, {"groupId": "OG002", "value": "1.81", "spread": "0.82"}, {"groupId": "OG003", "value": "1.64", "spread": "0.67"}]}]}, {"title": "12 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.66", "spread": "0.68"}, {"groupId": "OG001", "value": "1.68", "spread": "0.83"}, {"groupId": "OG002", "value": "1.76", "spread": "0.83"}, {"groupId": "OG003", "value": "1.56", "spread": "0.72"}]}]}, {"title": "23.16 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.66", "spread": "0.67"}, {"groupId": "OG001", "value": "1.69", "spread": "0.81"}, {"groupId": "OG002", "value": "1.68", "spread": "0.84"}, {"groupId": "OG003", "value": "1.52", "spread": "0.64"}]}]}, {"title": "23.75 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.74", "spread": "0.72"}, {"groupId": "OG001", "value": "1.73", "spread": "0.79"}, {"groupId": "OG002", "value": "1.79", "spread": "0.76"}, {"groupId": "OG003", "value": "1.62", "spread": "0.72"}]}]}]}, {"type": "SECONDARY", "title": "Standardized FEV1 AUC Between Baseline (Pre-dose) and 4 Hour Post-dose (AUC0-4h)", "description": "Spirometry was conducted according to internationally accepted standards at predose, 5, 15 and 30 minutes, 1, 2 and 4 hours post-dose on Day 1 and Day 7. The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 4 h post. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Day 1, Day 7", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.94", "lowerLimit": "2.90", "upperLimit": "2.99"}, {"groupId": "OG001", "value": "3.00", "lowerLimit": "2.95", "upperLimit": "3.05"}, {"groupId": "OG002", "value": "2.94", "lowerLimit": "2.89", "upperLimit": "2.99"}, {"groupId": "OG003", "value": "2.72", "lowerLimit": "2.68", "upperLimit": "2.77"}]}]}, {"title": "Day 7 (n=33,30,32,33)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.96", "lowerLimit": "2.92", "upperLimit": "3.00"}, {"groupId": "OG001", "value": "2.98", "lowerLimit": "2.93", "upperLimit": "3.02"}, {"groupId": "OG002", "value": "2.97", "lowerLimit": "2.93", "upperLimit": "3.02"}, {"groupId": "OG003", "value": "2.73", "lowerLimit": "2.68", "upperLimit": "2.77"}]}]}]}, {"type": "SECONDARY", "title": "Standardized FEV1 AUC Between Baseline (Pre-dose) and 12 Hour Post-dose (AUC0-12h)", "description": "Spirometry was conducted according to internationally accepted standards at predose, 5 , 15 and 30 min, 1, 2, 4, 8 and 12 hours post-dose on Day 1 and Day 7. The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 12 h post. Analysis of covariance with treatment, period, sequence and subject nested within sequence as fixed effects and FEV1 period baseline as a covariate.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Day 1, Day 7", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "31"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.90", "lowerLimit": "2.85", "upperLimit": "2.95"}, {"groupId": "OG001", "value": "2.94", "lowerLimit": "2.89", "upperLimit": "2.99"}, {"groupId": "OG002", "value": "2.87", "lowerLimit": "2.82", "upperLimit": "2.92"}, {"groupId": "OG003", "value": "2.68", "lowerLimit": "2.63", "upperLimit": "2.72"}]}]}, {"title": "Day 7 (n=31,29,30,31)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.93", "lowerLimit": "2.88", "upperLimit": "2.97"}, {"groupId": "OG001", "value": "2.92", "lowerLimit": "2.88", "upperLimit": "2.96"}, {"groupId": "OG002", "value": "2.91", "lowerLimit": "2.87", "upperLimit": "2.95"}, {"groupId": "OG003", "value": "2.70", "lowerLimit": "2.66", "upperLimit": "2.74"}]}]}]}, {"type": "SECONDARY", "title": "Peak Expiratory Flow Rate in the Morning in the Evening", "description": "PEFR was measured on all days from Screening Visit 2 to end of study visit: twice daily pre-dose (prior to Inhaled Corticosteroids) and approximately 12 hours post-dose (during the treatment period). Each subject was provided with a PEFR meter and recorded the PEFR readings in a daily diary. repeated measures. Analysis of covariance with treatment, period, sequence, day and treatment-day interaction as fixed effect and subject as a random effect and baseline PEFR as a covariate in the model.", "populationDescription": "Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters per second", "timeFrame": "Up to 101 days", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "33"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"title": "Morning", "categories": [{"measurements": [{"groupId": "OG000", "value": "451.33", "spread": "2.35"}, {"groupId": "OG001", "value": "447.15", "spread": "2.50"}, {"groupId": "OG002", "value": "444.11", "spread": "2.47"}, {"groupId": "OG003", "value": "421.58", "spread": "2.41"}]}]}, {"title": "Evening", "categories": [{"measurements": [{"groupId": "OG000", "value": "474.09", "spread": "2.18"}, {"groupId": "OG001", "value": "464.39", "spread": "2.33"}, {"groupId": "OG002", "value": "463.28", "spread": "2.30"}, {"groupId": "OG003", "value": "433.60", "spread": "2.24"}]}]}]}, {"type": "SECONDARY", "title": "Number of Puffs of Rescue Medicine", "description": "Salbutamol (100 \u00b5g/puff) was used as rescued medicine. The total number of puffs per day was calculated and divided by the number of days with data to determine the mean daily number of puffs of rescue medication for each patient and was recorded in the patient diary from Baseline until Day 8 of Treatment Period 4. Analysis of covariance with treatment, period, sequence, and subject nested within sequence as fixed effect.", "populationDescription": "Participants in the Pharmacodynamics Analysis set (included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement) who used rescue medication.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Puffs/day", "timeFrame": "Up to 101 days", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.98", "lowerLimit": "1.90", "upperLimit": "2.06"}, {"groupId": "OG001", "value": "1.90", "lowerLimit": "1.83", "upperLimit": "1.98"}, {"groupId": "OG002", "value": "1.91", "lowerLimit": "1.82", "upperLimit": "2.00"}, {"groupId": "OG003", "value": "1.94", "lowerLimit": "1.87", "upperLimit": "2.00"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events as a Measure of Safety", "description": "Adverse event are defined as any unfavorable and unintended diagnosis, symptoms, sign (including an abnormal lab finding), syndrome or disease which either occurs during the study, having been absent at baseline, or if present at baseline appear to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization , cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards. Additional information about adverse events can be found in the Adverse Event section", "populationDescription": "Safety population inlcuded all participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to 101 days", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "33"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "17"}, {"groupId": "OG003", "value": "10"}]}]}]}, {"type": "SECONDARY", "title": "Time to Reach Maximum Concentration (Tmax) After Drug Administration", "populationDescription": "PK Analysis Set", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Hours", "timeFrame": "Day1, Day 7", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "33"}]}], "classes": [{"title": "Day 1 (n=31,30,31)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.27", "lowerLimit": "0.22", "upperLimit": "1.03"}, {"groupId": "OG001", "value": "0.48", "lowerLimit": "0.20", "upperLimit": "0.58"}, {"groupId": "OG002", "value": "0.48", "lowerLimit": "0.20", "upperLimit": "1.00"}]}]}, {"title": "Day 7 (n=33,31,31)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.25", "lowerLimit": "0.08", "upperLimit": "0.75"}, {"groupId": "OG001", "value": "0.48", "lowerLimit": "0.22", "upperLimit": "0.98"}, {"groupId": "OG002", "value": "0.25", "lowerLimit": "0.22", "upperLimit": "1.02"}]}]}]}, {"type": "SECONDARY", "title": "Observed Maximum Concentration (Cmax) After Drug Administration", "populationDescription": "PK Analysis Set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Day 1, Day 7", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "33"}]}], "classes": [{"title": "Day 1 (n=31,30,31)", "categories": [{"measurements": [{"groupId": "OG000", "value": "72.9", "spread": "25.7"}, {"groupId": "OG001", "value": "124", "spread": "55.7"}, {"groupId": "OG002", "value": "64.2", "spread": "27.9"}]}]}, {"title": "Day 7 (n=33,31,31)", "categories": [{"measurements": [{"groupId": "OG000", "value": "112", "spread": "27.1"}, {"groupId": "OG001", "value": "174", "spread": "61.4"}, {"groupId": "OG002", "value": "90.5", "spread": "23.9"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Curve Pre-dose to 24 Hour Post Dose (AUC0-24h)", "populationDescription": "PK Analysis Set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hour*pg/mL", "timeFrame": "Day 1, Day 7", "groups": [{"id": "OG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days."}, {"id": "OG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days."}, {"id": "OG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "33"}]}], "classes": [{"title": "Day 1 (n=30,30,27)", "categories": [{"measurements": [{"groupId": "OG000", "value": "501", "spread": "149"}, {"groupId": "OG001", "value": "802", "spread": "308"}, {"groupId": "OG002", "value": "451", "spread": "134"}]}]}, {"title": "Day 7 (n=33,31,31)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1110", "spread": "273"}, {"groupId": "OG001", "value": "1770", "spread": "522"}, {"groupId": "OG002", "value": "952", "spread": "287"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "description": "The number of participants at risk for serious adverse events and non-serious adverse events is based on those participants in the arm who received at least one dose of study drug.", "eventGroups": [{"id": "EG000", "title": "75 \u00b5g Indacaterol (LB)", "description": "75 \u00b5g indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 34, "otherNumAffected": 14, "otherNumAtRisk": 34}, {"id": "EG001", "title": "75 \u00b5g Indacaterol (PoS)", "description": "75 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 31, "otherNumAffected": 16, "otherNumAtRisk": 31}, {"id": "EG002", "title": "37.5 \u00b5g Indacaterol (PoS)", "description": "37.5 \u00b5g indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 33, "otherNumAffected": 17, "otherNumAtRisk": 33}, {"id": "EG003", "title": "Placebo", "description": "Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.", "seriousNumAffected": 1, "seriousNumAtRisk": 33, "otherNumAffected": 9, "otherNumAtRisk": 33}], "seriousEvents": [{"term": "Ligament rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 33}]}], "otherEvents": [{"term": "Conjunctivitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 33}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 33}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 33}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Product taste abnormal", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Gastritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Excoriation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 33}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Muscle rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Soft tissue injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Sunburn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Hyperlipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 33}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Dry throat", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Increased upper airway secretion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 33}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 33}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 33}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000030272", "term": "Maleic acid"}], "ancestors": [{"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M245808", "name": "Maleic acid", "asFound": "Fast", "relevance": "HIGH"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}